ProCE Banner Activity

New Adjuvant Treatment Strategies for Early-Stage HER2-Positive Breast Cancer

Multimedia
Watch this on-demand Webcast from Madelaine Kuiper, NP, as she discusses the optimal use of dual HER2-targeted neoadjuvant and adjuvant therapy with trastuzumab and pertuzumab as well as the use of extended therapy with neratinib for patients with HER2+ EBC.

Released: November 13, 2018

Expiration: November 12, 2019

No longer available for credit.

Share

Faculty

Madelaine Kuiper

Madelaine Kuiper, NP

Nurse Practitioner
Department of Hematology/Oncology
University of California, Los Angeles
Santa Monica, California

Provided by

Provided by Postgraduate Institute for Medicine
ProCE Banner

Supporters

This activity is supported by educational grants from

Genentech TEXT Only

Puma Biotechnology, Inc.

Target Audience

This program is intended for oncology nurses and other healthcare providers who care for patients with HER2-positive early breast cancer.

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Support patient engagement and decision making through education and communication
  • Explain to patients with HER2-positive early breast cancer how adjuvant therapy can be individualized, considering the available clinical evidence, expert recommendations, and their goals and preferences
  • Identify subsets of patients most likely to benefit from adjuvant therapy with dual HER2 inhibition and/or extended adjuvant therapy with neratinib
  • Discuss the benefits and risks of intensifying and/or extending adjuvant therapy with patients with HER2-positive early breast cancer
  • Manage treatment-related symptoms experienced by patients with HER2-positive early breast cancer

Disclosure

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Faculty Disclosure

Primary Author

Madelaine Kuiper, NP

Nurse Practitioner
Department of Hematology/Oncology
University of California, Los Angeles
Santa Monica, California

Madelaine Kuiper, NP, has disclosed that she has received fees for non-CME/CE services from Novartis.

Staff Disclosure

Staff

Gordon Kelley,

Clinical Editor
Clinical Care Options, LLC

Gordon Kelley has no real or apparent conflicts of interest to report.

Kevin Obholz, PhD

Editorial Director, Hematology/Oncology

Kevin Obholz, PhD, has no real or apparent conflicts of interest to report.

Timothy A. Quill, PhD

Senior Managing Editor

Timothy Quill, PhD, has no real or apparent conflicts of interest to report.

Kristen Rosenthal, PhD

Clinical Editor

Kristen M. Rosenthal, PhD, has no real or apparent conflicts of interest to report.

Instructions for Credit

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Clinical Care Options, LLC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Credit Designation

The maximum number of hours awarded for this Continuing Nursing Education activity is 0.7 contact hour.

Disclosure of Unlabeled Use

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

The PIM planners and managers have nothing to disclose.

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners.  Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Additional Information

Participation in this self-study activity should be completed in approximately 0.7 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from November 13, 2018, through November 12, 2019:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Program Medium

This program has been made available online.


Goal


The goal of this activity is to improve oncology nurses’ ability to educate, partner in shared decision making with, and optimally care for patients with HER2-positive early breast cancer.